Harald Reinhart
Net worth: 989 590 $ as of 2024-05-30
Career history of Harald Reinhart
Former positions of Harald Reinhart
| Companies | Position | Start | End |
|---|---|---|---|
| ZAI LAB LIMITED | Corporate Officer/Principal | 2016-12-31 | 2024-06-29 |
Shionogi, Inc.
 Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Corporate Officer/Principal | - | - |
Training of Harald Reinhart
| Julius-Maximilians-Universität Würzburg | Doctorate Degree |
Statistics
International
| China | 2 |
| United States | 2 |
| Germany | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ZAI LAB LIMITED | Health Technology |
| Private companies | 1 |
|---|---|
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Health Technology |
- Stock Market
- Insiders
- Harald Reinhart
- Experience
